ATRC - AtriCure GAAP EPS of -$0.09 beats by $0.09 revenue of $88M beats by $0.1M

• AtriCure press release ( NASDAQ: ATRC ): Q4 GAAP EPS of -$0.09 beats by $0.09 .
• Revenue of $88M (+20.2% Y/Y) beats by $0.1M .

• Adjusted EBITDA was positive for the fourth quarter 2022 at $6.0 million, compared to negative $2.1 million for fourth quarter of 2021. Adjusted loss per share for the fourth quarter 2022 was $0.09 compared to $0.30 for the fourth quarter 2021.

• Revenue for 2022 was $330.4 million, an increase of $56.1 million or 20.4% (an increase of 21.8% on a constant currency basis), compared to 2021 revenue. U.S. revenue increased 21.0% to $277.2 million.

• International revenue was $53.2 million, an increase of $8.0 million or 17.7% (an increase of 25.7% on a constant currency basis).

• Gross profit for 2022 was $245.9 million compared to $205.9 million for 2021, and gross margin decreased to 74.4% for 2022 compared to 75.0% for 2021

• 2023 Financial Guidance

• Full year 2023 revenue is projected to be approximately $380 million to $387 million, reflecting growth of approximately 15% to 17% over full year 2022.

• Full year 2023 adjusted EBITDA is expected to break even, with improvements annually thereafter.

• Full year 2023 adjusted loss per share is expected to be in the range of $1.14 to $1.19.

For further details see: